Mirati Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Mirati Therapeutics sits in the top decile of US sponsors by registered trial count (#380 of 15,742 sponsors by registered trial count).
Mirati Therapeutics: 49 sponsored US clinical trials, 5 recruiting.
Mirati Therapeutics sponsors 49 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 28 completed. 4 of these trials are in Phase 3-4 (later-stage) and 45 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Cancer, with 3 trials.
Top-decile sponsor footprint
Mirati Therapeutics ranks in the top decile of sponsors by registered trial count (#380 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
28 of 41 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (68.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
49 total, page 1 of 1
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
NCT07415031
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04793958
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
NCT04685135
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249
Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets
NCT06801418
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
NCT05840510
A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
NCT05924152
A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib
NCT05868356
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
NCT05737706
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
NCT05578092
PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.
NCT05255276
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
NCT05178888
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
NCT04975256
A Study to Explore the Effect of Acid-reducing Agents
NCT04935112
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
NCT04887870
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
NCT04887194
A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib
NCT04800614
A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib
NCT04772612
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
NCT04518046
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
NCT04330664
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT03906071
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
NCT03680521
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
NCT03606174
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
NCT02954991
Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
NCT02805660
Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
NCT02544633
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
NCT02236195
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
NCT02219711
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
NCT02018926
Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State
NCT01930006
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
NCT00975767
Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
NCT00697632
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT00666497
Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies
NCT00679133
MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma
NCT00543582
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
NCT00511576
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
NCT00431873
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
NCT00372437
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
NCT00374296
Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
NCT00359086
Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
NCT00358982
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
NCT00324220
A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes
NCT00324129
A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes
NCT00324194
Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
NCT00323934
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 29 |
| Phase 2 | 16 |
| Phase 3 | 4 |
What is open in the Mirati Therapeutics pipeline
5 recruiting of 49 indexed (10% open); 28 completed (57%).
Phase mix: 4 late (III/IV) vs 45 early (I/II) (early-phase heavy).
Top condition: Advanced Cancer (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Mirati Therapeutics: open-pipeline peers nationwide
Peers matched on 49 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Mirati Therapeutics sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 49 trials (± recruiting share)
- Alnylam Pharmaceuticals · 49 trials · 29% recruiting
- argenx · 49 trials · 39% recruiting
- Braintree Laboratories · 49 trials · 0% recruiting
- Cynosure · 49 trials · 2% recruiting
Sponsors near 10% open enrollment (± trial volume)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 10% recruiting · 490 trials
- James J. Peters Veterans Affairs Medical Center · 10% recruiting · 39 trials
- California Pacific Medical Center Research Institute · 10% recruiting · 29 trials
- National Institute of Environmental Health Sciences (NIEHS) · 10% recruiting · 145 trials
Related
What to do with this Mirati Therapeutics page
49 registered trials is a research-attention snapshot, not an endorsement of Mirati Therapeutics or any single study.
- 5 of Mirati Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Cancer is the condition Mirati Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Mirati Therapeutics pipeline card: 49 registered trials from official public datasets.Report a data error.